Scientists at the University of British Columbia and BC Children’s Hospital are the first in Canada to use a new test for pediatric tumour analysis that may one day guide personalized treatments for children with cancer.
Working with researchers at Children’s Hospital Los Angeles and the Keck School of Medicine at the University of Southern California, the team analyzed 28 childhood tumour samples from nine cancer types archived in the BC Children’s Hospital Biobank.
They found that the pediatric cancer-focused test found more genetic mutations per sample compared with tests used to analyze adult cancers, and better identified weaknesses that can potentially be targeted with drugs.
“We are thinking of ways that we can use this technology in a more proactive way to study the child’s cancer early and prepare for a disease relapse prior to its occurrence.” Dr. Philipp Lange, co-senior study author
From extracting DNA from cancer cells, to sequencing and analyzing a sample, the whole process ideally takes two to three days in the lab. The new technology allows genes of interest to be amplified and can provide results for up to 16 patients in one week. At the end, researchers have a list of possible drugs that may target the pediatric cancer cells.
“Pediatric cancers are often very aggressive, so doing these types of tests need to be very fast,” said lead author Amanda Lorentzian, a UBC graduate student. “Using targeted sequencing allows for a fast turnaround time and a simple workflow. It has a lot of potential to inform better treatment options for pediatric patients.”
The results are part of Lorentzian’s work with Chris Maxwell and Philipp Lange, co-senior study authors, in an innovative field of cancer treatment research called precision oncology. Similar tests have been designed for adult cancers, but childhood cancers require a unique approach since different tissues are affected and fewer drugs are safe for treating children.
“This test uses DNA sequencing technology to look at thousands of specific regions in the tumour’s genome and identify changes or mutations in those areas,” said Maxwell, an associate professor in UBC’s department of pediatrics and investigator with the Michael Cuccione Childhood Cancer Research Program at BC Children’s Hospital.
Currently, most children diagnosed with cancer receive treatment and survive. For many cancer types there is greater than an 80 per cent cure rate, but the possibility of relapse is always looming.
“Because cure rates drop dramatically for children that suffer a cancer relapse, we hope this new technology may identify more targeted treatments,” said Lange, an assistant professor in UBC’s department of pathology and laboratory medicine, Canada Research Chair in Translational Proteomics of Pediatric Malignancies, and investigator with the Michael Cuccione Childhood Cancer Research Program at BC Children’s Hospital. “In addition, we are thinking of ways that we can use this technology in a more proactive way to study the child’s cancer early and prepare for a disease relapse prior to its occurrence.”
While proactive treatment plans are still years in the future following clinical trials, this study is the first step toward a personalized standard of care for childhood cancer patients.
The research was published in the Journal of the National Cancer Institute (JNCI) Cancer Spectrum. Funding was provided by the Michael Cuccione Childhood Cancer Foundation as part of the BRAvE Initiative at BC Children’s Hospital and supported by Team4Hope.
Credit UBC Faculty of Medicine story, January 23, 2019.